Osiris Therapeutics (OSIR) Tops Q3 Revs, Loss Views

November 5, 2012 8:08 AM EST Send to a Friend
Osiris Therapeutics (NASDAQ: OSIR) reported Q3 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.15 million versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment